MTOR Mutations in the Crosshairs of Targeted Therapy

Abstract

Summary: The identification of genetic lesions that affect tumor sensitivity to targeted therapies is a major objective of precision medicine. Two reports in this issue combine tumor genome analyses with functional characterization to uncover activating mutations in MTOR that confer sensitivity to a clinically used mTOR inhibitor. Cancer Discov; 4(5); 513–5. ©2014 AACR.

See related article by Wagle et al., p. 546

See related article by Grabiner et al., p. 554